These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 37641627)

  • 21. Targeting the gut barrier for the treatment of alcoholic liver disease.
    Zhou Z; Zhong W
    Liver Res; 2017 Dec; 1(4):197-207. PubMed ID: 30034913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alcohol, liver disease and the gut microbiota.
    Bajaj JS
    Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
    Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
    Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut Barrier and Microbiota in Cirrhosis.
    Philips CA; Augustine P
    J Clin Exp Hepatol; 2022; 12(2):625-638. PubMed ID: 35535069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of gut microbiota, exosomes, and their interaction in the pathogenesis of ALD.
    Cheng Z; Yang L; Chu H
    J Adv Res; 2024 Jul; ():. PubMed ID: 38969094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
    Mungamuri SK; Vijayasarathy K
    Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway.
    Kang Y; Kuang X; Yan H; Ren P; Yang X; Liu H; Liu Q; Yang H; Kang X; Shen X; Tong M; Li L; Wang X; Guo L; Ma J; Zhang F; Fan W
    mSystems; 2023 Apr; 8(2):e0112722. PubMed ID: 36794950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction.
    LeFort KR; Rungratanawanich W; Song BJ
    Cell Mol Life Sci; 2024 Jan; 81(1):34. PubMed ID: 38214802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
    Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.
    Park JW; Kim SE; Lee NY; Kim JH; Jung JH; Jang MK; Park SH; Lee MS; Kim DJ; Kim HS; Suk KT
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of alcoholic liver disease: role of oxidative metabolism.
    Ceni E; Mello T; Galli A
    World J Gastroenterol; 2014 Dec; 20(47):17756-72. PubMed ID: 25548474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.
    Liu J; Yang D; Wang X; Asare PT; Zhang Q; Na L; Shao L
    Front Cell Infect Microbiol; 2022; 12():774335. PubMed ID: 35444959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut Microbiota: Target for Modulation of Gut-Liver-Adipose Tissue Axis in Ethanol-Induced Liver Disease.
    Patel D; Sharma D; Mandal P
    Mediators Inflamm; 2022; 2022():4230599. PubMed ID: 35633655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inulin Ameliorates Alcoholic Liver Disease via Suppressing LPS-TLR4-Mψ Axis and Modulating Gut Microbiota in Mice.
    Yang X; He F; Zhang Y; Xue J; Li K; Zhang X; Zhu L; Wang Z; Wang H; Yang S
    Alcohol Clin Exp Res; 2019 Mar; 43(3):411-424. PubMed ID: 30589437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.